Stereoselective Dioxygenation of a Racemic Tryptophan Derivative catalysed by Chiral Manganese Porphyrins

Katsutoshi Ohku bo,* Takashi Sagawa, Mutsuo Kuwata, Tsuguru Hata, and Hitoshi lshida

Department of Applied Chemistry, Faculty of Engineering, Kumamoto University, Kumamoto 860, Japan

The first asymmetric dioxygenation reactions of the racemic tryptophan derivatives, N-acetyl-L-(+)- [and o-(-)]-tryptophan methyl ester, are reported, in which predominant generation of methyl 2-p-acetoamido-3-(2-formamidobenzoyl)propionate has been achieved in 23.3% enantiomeric excess in the catalytic system using the manganese complex of $\alpha, \alpha, \alpha, \alpha$ -tetrakis[o - $($ - $)$ -camphanoylamido)phenyl]porphyrin.

Asymmetric reactions in catalytic systems are of wide interest there is no report on an asymmetric reaction as a dioxygenase in connection with enzymatic reactions. Recently, many model. We report here the first stereosele in connection with enzymatic reactions. Recently, many model. We report here the first stereoselective dioxygenation mono-¹ and di-oxygenase models² using transition metal of the racemic tryptophan derivatives, N-acet mono-¹ and di-oxygenase models² using transition metal of the racemic tryptophan derivatives, N-acetyl-L-($+$)- [and complexes have been investigated, and asymmetric mono- $p-(-)$]-tryptophan methyl esters (1) to give $p-(-)$]-tryptophan methyl esters **(1)** to give a total dioxygen oxygenation reactions have already been reported.3 However, inserted ring-opening product having an asymmetric centre:

methyl 2-p-(-) or *L*-(+)-acetoamido-3-(2-formamidobenzoy1)propionate **(2),** catalysed by chiral manganese porphyrin complexes (Scheme 1). *t*

The substrate **(1)** was prepared by a literature method.4The chiral porphyrins used as catalysts are shown in Scheme 2. The porphyrins *(5)* and **(6)** were prepared for the first time by the amide linkage reaction of **5,10,15,20-tetrakis(p-carboxy**phenyl)porphyrin with $D-(+)$ - α -methylbenzylamine and $L-(-)$ -menthylamine, respectively. The 5α , 10α , 15α , 20α substituted porphyrin (7) and the $5\alpha, 10\alpha, 15\alpha, 20\beta$ (8) and 5α ,10 α ,15 β ,20 β -isomers (9) were prepared according to the literature.⁵ The oxygenolyses of the racemates **(1)** (1.0×10^{-4}) mol) by the manganese porphyrin complex $(1.0 \times 10^{-5} \text{ mol})$ under an atmosphere of dioxygen was carried out at room temperature in tetrahydrofuran (5 cm³) for 3 days.^{\ddagger} The product **(2)** was identified with an authentic sample by ¹H n.m.r., i.r., mass, and electronic spectroscopy. The amounts of unchanged **(I)** and the product **(2)** were determined spectrophotometrically after separating them from the reaction mixtures by t.l.c. on silica gel [Merck F254; R_f 0.41 for (1) and 0.23 for (2) in ethyl acetate]; λ_{max} (ε) 290 (5230) and 281 nm (6140) for **(l),** and 320 (3620) and 258 nm (9460) for **(2)** in methanol. The selectivity was estimated from c.d. spectra $[\lambda_{\text{max}}]$, 220 nm for **(1)**, 250 nm for **(2)** in methanol].

The variations in c.d. spectra of unreacted **(l),** which was separated from the reaction solutions by t.l.c., around 220 nm with the conversion $(\%)$ were determined in the asymmetric oxygenation catalysed by the manganese complex *(5)* and are

1- The amounts of ring-opening by-products such as **(3)** and **(4)** in Scheme 1 are negligible in comparison with **(2),** and the other products are not ring opening products. Therefore, products other than **(2)** are not discussed in this communication.

 \ddagger The present reaction did not proceed in the absence of the catalyst.

shown in Figure 1(A). The proportion of the $L-(+)$ -isomer of the substrate increased owing to the predominant consumption of the D-(-)-isomer with the catalyst *(5).* On the other hand, in the oxygenation catalysed by **(6)** the L-(+)-isomer **(1)** was consumed predominantly with generation of the $L-(+)$ isomer **(2)** as shown in Figure 1(B) and (C), respectively. The

Scheme 2. Manganese porphyrins used as catalysts.

Table 1. Asymmetric oxygenation of the racemates **(1)** to give optically active (2), catalysed by chiral manganse porphyrins.^a

^a The reactions were carried out by keeping tetrahydrofuran (5 cm³) solutions containing the racemate (1) $(1.0 \times 10^{-4}$ mol) and the manganese porphyrin complex $(1.0 \times 10^{-5} \text{ mol})$ under atmospheric dioxygen at 298 K for 3 days. $\frac{b}{2}$ Manganese(III) porphyrin complexes are used as chloride salts. ^c Consumption of (1), estimated spectrophotometrically; see text for details. d Enantiomeric excess.

Figure 1. C.d. spectra of (1) (A, B) and (2) (C) separated from the reaction solution in the catalytic system of the chiral porphyrin complexes (5) **(A)** and *(6)* (B, C).

catalytic activities and selectivities for the asymmetric oxygenation of the racemates **(1)** using the chiral porphyrins **(5)**—**(9)** are summarised in Table 1. The conversions [consumption of **(l)]** using the equatorial type porphyrins *(5)* and **(6)** as catalysts were larger than those with the axial type porphyrins **(7)-(9).** Higher conversions of **(1)** and higher yields of **(2)** were observed in the catalytic systems containing Mn^{II} complexes rather than Mn^{III} porphyrin chlorides with the chiral porphyrins of *(5),* **(6),** and **(8),** although no difference of selectivity for **(2)** generation was observed between Mn" and MnIII.

The stereoselectivities were 2.6-19.3% e.e. in the consumption of **(1)** and 1.2-23.3% e.e. in the formation of **(2).** The equatorial manganese(II,III) porphyrin **(6)** possessing menthyl groups and the axial manganese(II) porphyrin (7) were found to be effective. The maximum optical yield for the generation of $p-(-)$ -(2) was 23.3% e.e. in the catalytic system using the axial complex of **(7).**

Received, 27th June 1988; Corn. 8/025471

References

1 I. Tabushi and K. Morimitsu, *J. Am. Chern. SOC.,* 1984, 105,6871;

C. L. Hill and B. C. Schardt, *ibid.,* 1980, 102,6374; J. T. Groves, **W.** J. Kruper, Jr., and R. C. Haushalter, *ibid.,* 1980, 102,6375; **Y.** Aoyama, T. Watanabe, H. Onda, and H. Ogoshi, *Tetrahedron Lett.,* 1983, 1183; J. R. Lindsay Smith and D. N. Mortimer, *J. Chern. SOC., Perkin Trans. 2,* 1986, 1743; B. D. Pooter and B. Meunier, *ibid.,* 1985, 1735; **S.** Takagi, E. Takahashi, T. K. Miyamoto, and Y. Sasaki, *Chern. Lett.,* 1986, 1275; K. **S.** Suslick and B. R. Cook, J. *Chern. SOC., Chern. Cornrnun.,* 1987, 200; M. Masui, K. Tsuchida, **Y.** Kimata, and **S.** Ozaki, *Chern. Pharm. Bull.,* 1987, 35, 3078.

- 2 **A.** Nishinaga, *Chern. Lett.,* 1975, 273; M. Goto, K. Mori, and T. Sakai, *Chern. Pharrn. Bull.,* 1985,33,2195; J. Tsuji, H. Kezuka, H. Takayanagi, and K. Miyamoto, *Bull. Chern. SOC. Jpn.,* 1981, 54, 2369; M. N. Dufour-Ricroch, A. L. Crumbliss, G. Johnston, and **A.** Gaudemer, *J. Mol. Catal.,* 1980, **7,** 277; T. Fujii, M. Ohta, K. Kouno, **Y.** Ono, and **Y.** Ueda, *Chern. Pharrn. Bull.,* 1984,32,4252; Z. Yoshida, H. Sugimoto, and H. Ogoshi, *Adv. Chern. Ser.,* 1980, 191, 307; K. Uchida, M. Soma, **S.** Naito, T. Ohnishi, and K. Tamaru, *Chern. Lett.,* 1978, 471.
- 3 J. T. Groves and R. **S.** Myers, *J. Am. Chern. SOC.,* 1983,105,5791; J. T. Groves and R. Newrnann, *ibid.,* 1987, 109, 5045.
- **4** E. Balogh-Hergovich and G. Speier, *J. Znorg. Biochern.,* 1980, 13, 297.
- *5* **S.** Takagi, T. K. Miyamoto, and **Y.** Sasaki, *Bull. Chern. SOC. Jpn.,* 1985, 58, 447.